Iovance Shares Tumble After Cell Therapy Data From Lung Cancer Trial

  • Iovance Biotherapeutics Inc IOVA has announced additional data for LN-145 in patients with metastatic non-small cell lung cancer (mNSCLC) enrolled in Cohort 3B of the basket study IOV-COM-202. 
  • The results demonstrate the feasibility of LN-145, a tumor-infiltrating lymphocyte TIL cell therapy in heavily pre-treated patients.
  • Following one-time treatment with LN-145 monotherapy, the overall response rate (ORR) is 21.4% in the full analysis set (n=28) and 25% in the efficacy-evaluable set (n=24), including one complete response (CR) and five partial responses (PR). 
  • One complete response and one partial response are ongoing at 20.7 months and 3.0 months, respectively, at a median study follow-up of 9.8 months. 
  • Iovance is enrolling patients in the IOV-LUN-202 study to investigate LN-145 in second-line mNSCLC where patients have progressed on prior ICI and chemotherapy. 
  • Price Action: IOVA shares are down 15.4% at $19.88 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsNon-Small Cell Lung Cancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!